146 related articles for article (PubMed ID: 9635526)
1. Relation between cellular doxorubicin binding ability to nuclear DNA and histologic response to preoperative chemotherapy in patients with osteosarcoma.
Kusuzaki K; Takeshita H; Murata H; Hirata M; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer; 1998 Jun; 82(12):2343-9. PubMed ID: 9635526
[TBL] [Abstract][Full Text] [Related]
2. Assessment of chemosensitivity in patients with malignant bone and soft tissue tumors using thallium-201 scintigraphy and doxorubicin binding assay.
Murata H; Kusuzaki K; Takeshita H; Hirata M; Hashiguchi S; Emoto K; Ashihara T; Hirasawa Y
Anticancer Res; 2000; 20(5C):3967-70. PubMed ID: 11268485
[TBL] [Abstract][Full Text] [Related]
3. Assessment of chemosensitivity in patients with osteogenic sarcoma using the doxorubicin binding assay.
Kumta SM; Leung PC; Chow L; To SH; Lee S; Cheng SH
J Surg Oncol; 1998 Jul; 68(3):169-72. PubMed ID: 9701209
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?
Hattinger CM; Fanelli M; Tavanti E; Vella S; Riganti C; Picci P; Serra M
Future Oncol; 2017 Apr; 13(8):673-677. PubMed ID: 28183198
[No Abstract] [Full Text] [Related]
5. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
6. Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas.
Kusuzaki K; Hirata M; Takeshita H; Murata H; Hashiguchi S; Ashihara T; Hirasawa Y
Cancer Lett; 1999 Apr; 138(1-2):203-8. PubMed ID: 10378794
[TBL] [Abstract][Full Text] [Related]
7. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
[TBL] [Abstract][Full Text] [Related]
10. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
11. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
13. Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities.
Kusuzaki K; Shinjo H; Murata H; Takeshita H; Hashiguchi S; Nozaki T; Emoto K; Ashihara T; Hirasawa Y
Anticancer Res; 2000; 20(5C):3813-6. PubMed ID: 11268459
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of multidrug resistance in osteosarcomas, analyzed by doxorubicin binding assay, and histologic response to chemotherapy.
Kusuzaki K; Hirata M; Hashiguchi S; Takeshita H; Murata H; Ashihara T; Hirasawa Y
Anticancer Res; 1999; 19(6B):5159-62. PubMed ID: 10697527
[TBL] [Abstract][Full Text] [Related]
15. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function.
Harisi R; Dudas J; Nagy-Olah J; Timar F; Szendroi M; Jeney A
Cancer Biol Ther; 2007 Aug; 6(8):1240-6. PubMed ID: 17703109
[TBL] [Abstract][Full Text] [Related]
16. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.
Baldini N; Scotlandi K; Serra M; Kusuzaki K; Shikita T; Manara MC; Maurici D; Campanacci M
J Cancer Res Clin Oncol; 1992; 119(2):121-6. PubMed ID: 1358894
[TBL] [Abstract][Full Text] [Related]
18. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.
Rha SY; Chung HC; Gong SJ; Shim KY; Ahn JB; Yang WI; Shin KH; Yoo NC; Kim JH; Roh JK; Lee CI; Kim BS
Oncol Rep; 1999; 6(3):631-7. PubMed ID: 10203605
[TBL] [Abstract][Full Text] [Related]
19. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma.
Nathan SS; DiResta GR; Casas-Ganem JE; Hoang BH; Sowers R; Yang R; Huvos AG; Gorlick R; Healey JH
Clin Cancer Res; 2005 Mar; 11(6):2389-97. PubMed ID: 15788690
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
